Chapter 151 : Susceptibility Test Methods: Parasites

MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.

Preview this chapter:
Zoom in

Susceptibility Test Methods: Parasites, Page 1 of 2

| /docserver/preview/fulltext/10.1128/9781555817381/9781555817381.ch151-1.gif /docserver/preview/fulltext/10.1128/9781555817381/9781555817381.ch151-2.gif


Accurate methods for ascertaining responses of parasites to antiparasitic drugs can prove useful at several levels. They can assist in the clinical management of individual patients, they can yield epidemiologic information that may guide drug use policies and public health interventions, and they offer crucial research tools for the development of new and better drugs. Drug susceptibility tests fall into three broad categories: tests, tests, and molecular tests. tests with patients directly assess the clinical efficacies of existing compounds. Their interpretation is limited by potential interference by factors related to the host or to the environment. tests circumvent these interferences by isolating the parasites from their hosts and investigating them in culture under controlled laboratory conditions, with opportunities for repeated assessments against multiple compounds, including experimental compounds. Molecular tests detect genetic variations that are potentially linked with resistance. Such tests offer unique advantages. PCRs can be performed with minute amounts of nonviable parasite genetic material. They can be run in batches, allowing large-scale epidemiologic studies. Because of their short duration (hours), molecular diagnostic procedures can potentially be used to guide patient management. These different categories of tests provide complementary information. They are discussed for five parasitic diseases, selected for their particular chemotherapeutic challenges: malaria, trichomoniasis, leishmaniasis, African trypanosomiasis, and schistosomiasis.

Citation: Le Bras J, Clain J, Secor W. 2015. Susceptibility Test Methods: Parasites, p 2563-2571. In Jorgensen J, Pfaller M, Carroll K, Funke G, Landry M, Richter S, Warnock D (ed), Manual of Clinical Microbiology, Eleventh Edition. ASM Press, Washington, DC. doi: 10.1128/9781555817381.ch151
Highlighted Text: Show | Hide
Loading full text...

Full text loading...


1. World Health Organization. 2003. Assessment and Monitoring of Antimalarial Drug Efficacy for the Treatment of Uncomplicated Falciparum Malaria. WHO/HTM/RBM/2003.50. World Health Organization, Geneva, Switzerland.
2. World Health Organization. 2005. Susceptibility of P. falciparum to Antimalarial Drugs: Report on Global Monitoring: 1996–2004. WHO/HTM/MAL/2005.1103. World Health Organization, Geneva, Switzerland.
3. Flegg JA,, Guerin PJ,, White NJ,, Stepniewska K. 2011. Standardizing the measurement of parasite clearance in falciparum malaria: the parasite clearance estimator. Malar J 10: 339.
4. Price RN,, Dorsey G,, Ashley EA,, Barnes KI,, Baird JK,, d’Alessandro U,, Guerin PJ,, Laufer MK,, Naidoo I,, Nosten F,, Olliaro P,, Plowe CV,, Ringwald P,, Sibley CH,, Stepniewska K,, White NJ. 2007. World Antimalarial Resistance Network. I: Clinical efficacy of antimalarial drugs. Malar J 6: 119.
5. White NJ. 2002. The assessment of antimalarial drug efficacy. Trends Parasitol 18: 458464.
6. Barnes KI,, Watkins WM,, White NJ. 2008. Antimalarial dosing regimens and drug resistance. Trends Parasitol 24: 127134.
7. Trager W,, Jensen JB. 1976. Human malaria parasites in continuous culture. Science 193: 673675.
8. Rieckmann KH,, Sax LJ,, Campbell GH,, Mrema JE. 1978. Drug sensitivity of Plasmodium falciparum. An in-vitro microtechnique. Lancet i: 2223.
9. World Health Organization . 2001. In Vitro Micro-Test (Mark III) for the Assessment of P. falciparum Susceptibility to Chloroquine, Mefloquine, Quinine, Amodiaquine, Sulfadoxine/Pyrimethamine and Artemisinin. CTD/MAL/9720 Rev 2. World Health Organization, Geneva, Switzerland.
10. Desjardins RE,, Canfield CJ,, Haynes JD,, Chulay JD. 1979. Quantitative assessment of antimalarial activity in vitro by a semiautomated microdilution technique. Antimicrob Agents Chemother 16: 710718.
11. Moreno A,, Brasseur P,, Cuzin-Ouattara N,, Blanc C,, Druilhe P. 2001. Evaluation under field conditions of the colourimetric DELI-microtest for the assessment of Plasmodium falciparum drug resistance. Trans R Soc Trop Med Hyg 95: 100103.
12. Noedl H,, Attlmayr B,, Wernsdorfer WH,, Kollaritsch H,, Miller RS. 2004. A histidine-rich protein 2-based malaria drug sensitivity assay for field use. Am J Trop Med Hyg 71: 711714.
13. Kaddouri H,, Nakache S,, Houze S,, Mentre F,, Le Bras J. 2006. Susceptibility of Plasmodium falciparum clinical isolates from Africa using a highly sensitive Plasmodium lactate dehydrogenase immunodetection assay and inhibitory maximum effect model for precise measurement of the 50-percent inhibitory concentration. Antimicrob Agents Chemother 50: 33433349.
14. Smilkstein M,, Sriwilaijaroen N,, Kelly JX,, Wilairat P,, Riscoe M. 2004. Simple and inexpensive fluorescence-based technique for high-throughput antimalarial drug screening. Antimicrob Agents Chemother 48: 18031806.
15. Bacon DJ,, Latour C,, Lucas C,, Colina O,, Ringwald P,, Picot S. 2007. Comparison of a SYBR green I-based assay with a histidine-rich protein II enzyme-linked immunosorbent assay for in vitro antimalarial drug efficacy testing and application to clinical isolates. Antimicrob Agents Chemother 51: 11721178.
16. Rason MA,, Randriantsoa T,, Andrianantenaina H,, Ratsimbasoa A,, Ménard D. 2008. Performance and reliability of the SYBR Green I based assay for the routine monitoring of susceptibility of P. falciparum clinical isolates. Trans R Soc Trop Med Hyg 102: 346351.
17. Duraisingh MT,, Jones P,, Sambou I,, von Seidlein L,, Pinder M,, Warhurst DC. 1999. Inoculum effect leads to overestimation of in vitro resistance for artemisinin derivatives and standard antimalarials: a Gambian field study. Parasitology 119: 435440.
18. Wang P,, Sims PF,, Hyde JE. 1997. A modified in vitro sulfadoxine susceptibility assay for Plasmodium falciparum suitable for investigating Fansidar resistance. Parasitology 115: 223230.
19. Basco LK. 2004. Molecular epidemiology of malaria in Cameroon. XX. Experimental studies on various factors of in vitro drug sensitivity assays using fresh isolates of P. falciparum. Am J Trop Med Hyg 70: 474480.
20. Basco LK. 2003. Molecular epidemiology of malaria in Cameroon. XV. Experimental studies on serum substitutes and supplements and alternative culture media for in vitro drug sensitivity assays using fresh isolates of P. falciparum. Am J Trop Med Hyg 69: 168173.
21. Bacon DJ,, Jambou R,, Fandeur T,, Le Bras J,, Wongsrichanalai C,, Fukuda MM,, Ringwald P,, Sibley CH,, Kyle DE. 2007. An in vitro antimalarial drug susceptibility database: a component of the World Antimalarial Resistance Network (WARN) database. Malar J 6: 120124.
22. Le Nagard H,, Vincent C,, Mentré F,, Le Bras J. 2011. Online analysis of in vitro resistance to antimalarial drugs through nonlinear regression. Comput Methods Programs Biomed 104: 1018.
23. Woodrow CJ,, Dahlström S,, Cooksey R,, Flegg JA,, Le Nagard H,, Mentré F,, Murillo C,, Ménard D,, Nosten F,, Sriprawat K,, Musset L,, Quashie NB,, Lim P,, Fairhurst RM,, Nsobya SL,, Sinou V,, Noedl H,, Pradines B,, Johnson JD,, Guerin PJ,, Sibley CH,, Le Bras J. 2013. High-throughput analysis of antimalarial susceptibility data by the WorldWide Antimalarial Resistance Network (WWARN) in vitro analysis and reporting tool. Antimicrob Agents Chemother 57: 31213130.
24. Klonis N,, Xie SC,, McCaw JM,, Crespo-Ortiz MP,, Zaloumis SG,, Simpson JA,, Tilley L. 2013. Altered temporal response of malaria parasites determines differential sensitivity to artemisinin. Proc Natl Acad Sci USA 110: 51575162.
25. Witkowski B,, Amaratunga C,, Khim N,, Sreng S,, Chim P,, Kim S,, Lim P,, Mao S,, Sopha C,, Sam B,, Anderson JM,, Duong S,, Chuor CM,, Taylor WR,, Suon S,, Mercereau-Puijalon O,, Fairhurst RM,, Ménard D. 2013. Novel phenotypic assays for the detection of artemisinin-resistant Plasmodium falciparum malaria in Cambodia: in-vitro and ex-vivo drug response studies. Lancet Infect Dis 13: 10431049.
26. Witkowski B,, Khim N,, Chim P,, Kim S,, Ke S,, Kloeung N,, Chy S,, Duong S,, Leang R,, Ringwald P,, Dondorp AM,, Tripura R,, Benoit-Vical F,, Berry A,, Gorgette O,, Ariey F,, Barale JC,, Mercereau-Puijalon O,, Ménard D. 2013. Reduced artemisinin susceptibility of Plasmodium falciparum ring stages in western Cambodia. Antimicrob Agents Chemother 57: 914923.
27. Delves M,, Plouffe D,, Scheurer C,, Meister S,, Wittlin S,, Winzeler EA,, Sinden RE,, Leroy D. 2012. The activities of current antimalarial drugs on the life cycle stages of Plasmodium: a comparative study with human and rodent parasites. PLoS Med 9: e1001169. doi:10.1371/journal. pmed.1001169.
28. Tasanor O,, Noedl H,, Na-Banchang K,, Congpuong K,, Sirichaisinthop J,, Wernsdorfer WH. 2002. An in vitro system for assessing the sensitivity of Plasmodium vivax to chloroquine. Acta Trop 83: 4961.
29. Stahel E,, Mazier D,, Guillouzo A,, Miltgen F,, Landau I,, Mellouk S,, Beaudoin RL,, Langlois P,, Gentilini M. 1988. Iron chelators: in vitro inhibitory effect on the liver stage of rodent and human malaria. Am J Trop Med Hyg 39: 236240.
30. Coleman RE,, Nath AK,, Schneider I,, Song G-H,, Klein TA,, Milhous WK. 1994. Prevention of sporogony of Plasmodium falciparum and P. berghei in Anopheles stephensi mosquitoes by transmission-blocking antimalarials. Am J Trop Med Hyg 50: 646653.
31. Fidock DA,, Nomura T,, Talley AK,, Cooper RA,, Dzekunov SM,, Ferdig MT,, Ursos LMB,, Sidhu ABS,, Naudé B,, Deitsch KW,, Su X,, Wootton JC,, Roepe PD,, Wellems TE. 2000. Mutations in the P. falciparum digestive vacuole transmembrane protein PfCRT and evidence for their role in chloroquine resistance. Mol Cell 6: 861871.
32. Ecker A,, Lehane AM,, Clain J,, Fidock DA. 2012. PfCRT and its role in antimalarial drug resistance. Trends Parasitol 28: 504511.
33. Pickard AL,, Wongsrichanalai C,, Purfield A,, Kamwendo D,, Emery K,, Zalewski C,, Kawamoto F,, Miller RS,, Meshnick SR. 2003. Resistance to antimalarials in Southeast Asia and genetic polymorphisms in pfmdr1. Antimicrob Agents Chemother 47: 24182423.
34. Price RN,, Uhlemann AC,, Brockman A,, McGready R,, Ashley E,, Phaipun L,, Patel R,, Laing K,, Looareesuwan S,, White NJ,, Nosten F,, Krishna S. 2004. Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number. Lancet 364: 438447.
35. Valderramos SG,, Fidock DA. 2006. Transporters involved in resistance to antimalarial drugs. Trends Pharmacol Sci 27: 594601.
36. Ariey F,, Witkowski B,, Amaratunga C,, Beghain J,, Langlois AC,, Khim N,, Kim S,, Duru V,, Bouchier C,, Ma L,, Lim P,, Leang R,, Duong S,, Sreng S,, Suon S,, Chuor CM,, Bout DM,, Ménard S,, Rogers WO,, Genton B,, Fandeur T,, Miotto O,, Ringwald P,, Le Bras J,, Berry A,, Barale JC,, Fairhurst RM,, Benoit-Vical F,, Mercereau-Puijalon O,, Ménard D. 2014. A molecular marker of artemisinin-resistant Plasmodium falciparum malaria. Nature 505: 5055.
37. Peterson DS,, Walliker D,, Wellems TE. 1988. Evidence that a point mutation in dihydrofolate reductase-thymidylate synthase confers resistance to pyrimethamine in falciparum malaria. Proc Natl Acad Sci USA 85: 91149118.
38. Cowman AF,, Morry MJ,, Biggs BA,, Cross GA,, Foote SJ. 1988. Amino acid changes linked to pyrimethamine resistance in the dihydrofolate reductase-thymidylate synthase gene of Plasmodium falciparum. Proc Natl Acad Sci USA 85: 91099113.
39. Müller IB,, Hyde JE. 2013. Folate metabolism in human malaria parasites—75 years on. Mol Biochem Parasitol 188: 6377.
40. Hastings MD,, Porter KM,, Maguire JD,, Susanti I,, Kania W,, Bangs MJ,, Sibley CH,, Baird JK. 2003. Dihydrofolate reductase mutations in Plasmodium vivax from Indonesia and therapeutic response to sulfadoxine plus pyrimethamine. J Infect Dis 189: 744750.
41. Sirawaraporn W,, Sathitkul T,, Sirawaraporn R,, Yuthavong Y,, Santi DV. 1997. Antifolate-resistant mutants of Plasmodium falciparum dihydrofolate reductase. Proc Natl Acad Sci USA 94: 11241129.
42. Nzila AM,, Mberu EK,, Sulo J,, Dayo H,, Winstanley PA,, Sibley CH,, Watkins WM. 2000. Towards an understanding of the mechanism of pyrimethamine-sulfadoxine resistance in Plasmodium falciparum: genotyping of dihydrofolate reductase and dihydropteroate synthase of Kenyan parasites. Antimicrob Agents Chemother 44: 991996.
43. Musset L,, Bouchaud O,, Matheron S,, Massias L,, Le Bras J. 2006. Clinical atovaquone-proguanil resistance of Plasmodium falciparum associated with cytochrome b codon 268 mutations. Microbes Infect 9: 25992604.
44. Djimdé A,, Doumbo OK,, Cortese JF,, Kayentao K,, Doumbo S,, Diourté Y,, Dicko A,, Su X,, Nomura T,, Fidock DA,, Wellems TE,, Plowe CV. 2001. A molecular marker for chloroquine-resistant falciparum malaria. N Engl J Med 344: 257263.
45. Basco LK,, Ringwald P. 2000. Molecular epidemiology of malaria in Yaounde, Cameroon. VI. Sequence variations in the Plasmodium falciparum dihydrofolate reductase-thymidylate synthase gene and in vitro resistance to pyrimethamine and cycloguanil. Am J Trop Med Hyg 62: 271276.
46. Syafruddin D,, Asih PB,, Casey GJ,, Maguire J,, Baird JK,, Nagesha HS,, Cowman AF,, Reeder JC. 2005. Molecular epidemiology of Plasmodium falciparum resistance to antimalarial drugs in Indonesia. Am J Trop Med Hyg 72: 174181.
47. Nair S,, Brockman A,, Paiphun L,, Nosten F,, Anderson TJ. 2002. Rapid genotyping of loci involved in antifolate drug resistance in Plasmodium falciparum by primer extension. Int J Parasitol 32: 852858.
48. Crameri A,, Marfurt J,, Mugittu K,, Maire N,, Regös A,, Coppee JY,, Sismeiro O,, Burki R,, Huber E,, Laubscher D,, Puijalon O,, Genton B,, Felger I,, Beck HP. 2007. Rapid microarray-based method for monitoring of all currently known single-nucleotide polymorphisms associated with parasite resistance to antimalaria drugs. J Clin Microbiol 45: 36853691.
49. Taylor SM,, Parobek CM,, Aragam N,, Ngasala BE,, Mårtensson A,, Meshnick SR,, Juliano JJ. 2013. Pooled deep sequencing of Plasmodium falciparum isolates: an efficient and scalable tool to quantify prevailing malaria drug-resistance genotypes. J Infect Dis 208: 19982006.
50. Hastings IM,, Smith TA. 2008. MalHaploFreq: a computer programme for estimating malaria haplotype frequencies from blood samples. Malar J 7: 130.
51. Dondorp AM,, Nosten F,, Yi P,, Das D,, Phyo AP,, Tarning J,, Lwin KM,, Ariey F,, Hanpithakpong W,, Lee SJ,, Ringwald P,, Silamut K,, Imwong M,, Chotivanich K,, Lim P,, Herdman T,, An SS,, Yeung S,, Singhasivanon P,, Day NP,, Lindegardh N,, Socheat D,, White NJ. 2009. Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med 361: 455467.
52. Lim P,, Dek D,, Try V,, Eastman RT,, Chy S,, Sreng S,, Suon S,, Mao S,, Sopha C,, Sam B,, Ashley EA,, Miotto O,, Dondorp AM,, White NJ,, Su XZ,, Char MC,, Anderson JM,, Amaratunga C,, Menard D,, Fairhurst RM. 2013. Ex vivo susceptibility of Plasmodium falciparum to antimalarial drugs in western, northern, and eastern Cambodia, 2011–2012: association with molecular markers. Antimicrob Agents Chemother 57: 52775283.
53. Sibley C,, Barnes KI,, Plowe CV. 2007. The rationale for creating a world antimalarial resistance network. Malar J 6: 13.
54. Vestergaard LS,, Ringwald P. 2007. Responding to the challenge of antimalarial drug resistance by routine monitoring to update national malaria treatment policies. Am J Trop Med Hyg 77: 153159.
55. Kirkcaldy RD,, Augostini P,, Asbel LE,, Bernstein KT,, Kerani RP,, Mettenbrink CJ,, Pathela P,, Schwebke JR,, Secor WE,, Workowski KA,, Davis D,, Braxton J,, Weinstock HS. 2012. Trichomonas vaginalis antimicrobial resistance in 6 US cities, STD Surveillance Network, 2009–2010. Emerg Infect Dis 18: 939943.
56. Secor WE. 2012. Trichomonas vaginalis: treatment questions and challenges. Expert Rev Anti Infect Ther 10: 107109.
57. Bosserman EA,, Helms DJ,, Mosure DJ,, Secor WE,, Workowski KA. 2011. Utility of antimicrobial susceptibility testing in Trichomonas vaginalis infected women with clinical treatment failure. Sex Transm Dis 38: 983987.
58. Meingassner JG,, Thurner J. 1979. Strain of Trichomonas vaginalis resistant to metronidazole and other 5-nitroimidazoles. Antimicrob Agents Chemother 15: 254257.
59. Müller M,, Lossick JG,, Gorrell TE. 1988. In vitro susceptibility of Trichomonas vaginalis and treatment outcome in vaginal trichomoniasis. Sex Transm Dis 15: 1724.
60. Crowell AL,, Stephens CE,, Kumar A,, Boykin DE,, Secor WE. 2004. Evaluation of dicationic compounds for activity against Trichomonas vaginalis. Antimicrob Agents Chemother 48: 36023605.
61. Goodhew EB,, Secor WE. 2013. Drug library screening against metronidazole-sensitive and -resistant Trichomonas vaginalis isolates. Sex Transm Infect 89: 479484.
62. Martínez-Grueiro MM,, Montero-Pereira D,, Giménez-Pardo C,, Nogal-Ruiz JJ,, Escario JA,, Gómez-Barrio A. 2003. Trichomonas vaginalis: determination of acid phosphatase activity as a pharmacological screening procedure. J Parasitol 89: 10761077.
63. Hampl V,, Vanˇáčová S,, Kulda J,, Fleger J. 2001. Concordance between genetic relatedness and phenotypic similarities of Trichomonas vaginalis strains. BMC Evol Biol 1: 11.
64. Snipes LJ,, Gamard PM,, Narcisi EM,, Beard CB,, Lehmann T,, Secor WE. 2000. Molecular epidemiology of metronidazole resistance in a population of Trichomonas vaginalis clinical isolates. J Clin Microbiol 38: 30043009.
65. Meade JC,, de Mestral J,, Stiles JK,, Secor WE,, Finley RW,, Cleary JD,, Lushbaugh WB. 2009. Genetic diversity of Trichomonas vaginalis clinical isolates determined by EcoR1 restriction fragment length polymorphism of heat-shock protein 70 genes. Am J Trop Med Hyg 80: 245251.
66. Conrad M,, Gorman A,, Schillinger JA,, Fiori PL,, Arroyo R,, Malla N,, Dubey ML,, Gonzalez J,, Blank S,, Secor WE,, Carlton JM. 2012. Population genetics of the sexually transmitted pathogen Trichomonas vaginalis and evidence for sexual recombination. PLoS Negl Trop Dis 6: e1573. doi:10.1371/journal.pntd.0001573.
67. Callahan HL,, Portal AC,, Devereaux R,, Grögl M. 1997. An axenic amastigote system for drug screening. Antimicrob Agents Chemother 41: 818822.
68. Grögl M,, Thomason TN,, Franke ED. 1992. Drug resistance in leishmaniasis: its implication in systemic chemotherapy of cutaneous and mucocutaneous disease. Am J Trop Med Hyg 47: 117126.
69. Bodley AL,, McGarry MW,, Shapiro TA. 1995. Drug cytotoxicity assay for African trypanosomes and Leishmania species. J Infect Dis 172: 11571159.
70. Sereno D,, Lemesre J-L. 1997. Axenically cultured amastigote forms as an in vitro model for investigation of antileishmanial agents. Antimicrob Agents Chemother 41: 972976.
71. Mikus J,, Steverding D. 2000. A simple colorimetric method to screen drug cytotoxicity against Leishmania using the dye Alamar Blue®. Parasitol Int 48: 265269.
72. Vermeersch M,, da Luz RI,, Toté K,, Timmermans J-P,, Cos P,, Maes L. 2009. In vitro susceptibilities of Leishmania donovani promastigote and amastigote stages to antileishmanial reference drugs: practical relevance to stage-specific differences. Antimicrob Agents Chemother 53: 38553859.
73. Kulshrestha A,, Bhandari V,, Mukhopadhyay R,, Ramesh V,, Sundar S,, Maes L,, Dujardin JC,, Roy S,, Salotra P. 2013. Validation of a simple-resazurin-based promastigote assay for the routine monitoring of miltefosine susceptibility in clinical isolates of Leishmania donovani. Parasitol Res 112: 825828.
74. Lira R,, Sundar S,, Makharia A,, Kenney R,, Gam A,, Saraiva E,, Sacks D. 1999. Evidence that the high incidence of treatment failures in Indian kala-azar is due to the emergence of antimony-resistant strains of Leishmania donovani. J Infect Dis 180: 564567.
75. Aït-Oudhia K,, Gazanion E,, Vergnes B,, Oury B,, Sereno D. 2011. Leishmania antimony resistance: what we know what we can learn from the field. Parasitol Res 109: 12251232.
76. da Luz RI,, Vermeersch M,, Dujardin J-C,, Cos P,, Maes L. 2009. In vitro sensitivity testing of Leishmania field isolates: preconditioning of promastigotes enhances infectivity for macrophage host cells. Antimicrob Agents Chemother 53: 51975203.
77. Rijal S,, Yardley V,, Chappuis F,, Decuypere S,, Khanal B,, Singh R,, Boelaert M,, De Doncker S,, Croft S,, Dujardin J-C. 2007. Antimonial treatment of visceral leishmaniasis: are current in vitro susceptibility assays adequate for prognosis of in vivo therapy outcome? Microb Infect 9: 529535.
78. Sereno D,, Roy G,, Lemesre JL,, Papadopoulou B,, Ouellette M. 2001. DNA transformation of Leishmania infantum axenic amastigotes and their use in drug screening. Antimicrob Agents Chemother 45: 11681173.
79. Singh N,, Dube A. 2004. Fluorescent Leishmania: application to anti-leishmanial drug testing. Am J Trop Med Hyg 71: 400402.
80. Di Giorgio C,, Ridoux O,, Delmas F,, Azas N,, Gasquet M,, Timon-David P. 2000. Flow cytometric detection of Leishmania parasites in human monocyte-derived macrophages: application to antileishmanial-drug testing. Antimicrob Agents Chemother 44: 30743078.
81. Jain SK,, Sahu R,, Walker LA,, Tekwani BL. 2012. A parasite rescue and transformation assay for antileishmanial screening against intracellular Leishmania donovani amastigotes in THP1 human acute monocytic leukemia cell line. J Vis Exp 70: e4054. doi:10.3791/4054.
82. Vanaerschot M,, Decuypere S,, Downing T,, Imamura H,, Stark O,, De Doncker S,, Roy S,, Ostyn B,, Maes L,, Khanal B,, Boelaert M,, Schönian G,, Berriman M,, Chappuis F,, Dujardin J-C,, Sundar S,, Rijal S. 2012. Genetic markers for SSG resistance in Leishmania donovani and SSG treatment failure in visceral leishmaniasis patients of the Indian subcontinent. J Infect Dis 206: 752755.
83. Torres DC,, Ribeiro-Alves M,, Romero GAS,, Dávila AMR,, Cupolillo E. 2013. Assessment of drug resistance related genes as candidate markers for treatment outcome prediction of cutaneous leishmaniasis in Brazil. Acta Trop 126: 132141.
84. Kaminsky R,, Zweygarth E. 1989. Feeder layer-free in vitro assay for screening antitrypanosomal compounds against Trypanosoma brucei brucei and T. b. evansi. Antimicrob Agents Chemother 33: 881885.
85. Yarlett N,, Goldberg B,, Nathan HC,, Garofalo J,, Bacchi CJ. 1991. Differential sensitivity of Trypanosoma brucei rhodesiense isolate to in vitro lysis by arsenicals. Exp Parasitol 72: 205215.
86. Raz B,, Iten M,, Grether-Buhler Y,, Kaminsky R,, Brun R. 1997. The Alamar Blue® assay to determine drug sensitivity or African trypanosomes ( T. b. rhodesiense and T. b. gambiense) in vitro. Acta Trop 68: 139147.
87. Vincent IM,, Creek D,, Watson DG,, Kamleh MA,, Woods DJ,, Wong PE,, Burchmore RJS,, Barrett MP. 2010. A molecular mechanism for eflornithine resistance in African trypanosomes. PLoS Pathog 6: e1001204. doi:10.1371/journal.ppat.1001204.
88. Stewart ML,, Burchmore RJS,, Clucas C,, Hertz-Fowler C,, Brooks K,, Tait A,, MacLeod A,, Turner CMR,, de Koning HP,, Wong PE,, Barrett MP. 2010. Multiple genetic mechanisms lead to loss of functional TbAT1 expression in drug-resistant trypanosomes. Eukaryot Cell 9: 336343.
89. Maser P,, Sutterlin C,, Kralli A,, Kaminsky R. 1999. A nucleoside transporter from Trypanosoma brucei involved in drug resistance. Science 285: 242244.
90. Carter NS,, Barrett MP,, de Koning HP. 1999. A drug resistance determinant in Trypanosoma brucei. Trends Microbiol 7: 469471.
91. Black CL,, Steinauer ML,, Mwinzi PNM,, Secor WE,, Karanja DMS,, Colley DG. 2009. Impact of intense, longitudinal retreatment with praziquantel on cure rates of schistosomiasis mansoni in a cohort of occupationally exposed adults in western Kenya. Trop Med Int Health 14: 450457.
92. Guidi A,, Andolina C,, Ame SM,, Albonico M,, Cioli D,, Haji HJ. 2010. Praziquantel efficacy and long-term appraisal of schistosomiasis control in Pemba Island. Trop Med Int Health 15: 614618.
93. Wang W,, Dai J-R,, Li H-J,, Shen X-H,, Liang Y-S. 2010. Is there reduced susceptibility to praziquantel in Schistosoma japonicum? Evidence from China. Parasitology 137: 19051912.
94. Cioli D,, Botros SS,, Wheatcroft-Francklow K,, Mbaye A,, Southgate V,, Tchuenté L-AT,, Pica-Mattoccia L,, Troiani AR,, el-Din SHS,, Sabra A-NA,, Albin J,, Engels D,, Doenhoff MJ. 2004. Determination of ED 50 values for praziquantel in praziquantel-resistant and -susceptible Schistosoma mansoni isolates. Int J Parasitol 34: 979987.
95. Melman SD,, Steinauer ML,, Cunningham C,, Kubatko LS,, Mwangi IN,, Wynn NB,, Mutuki MW,, Karanja DMS,, Colley DG,, Black CL,, Secor WE,, Mkoji GM,, Loker ES. 2009. Reduced susceptibility to praziquantel among naturally occurring Kenyan isolates of Schistosoma mansoni. PLoS Negl Trop Dis 3: e504. doi:10.1371/journal.pntd.0000504.
96. Pica-Mattoccia L,, Cioli C. 2004. Sex- and stage-related sensitivity of Schistosoma mansoni to in vivo and in vitro praziquantel treatment. Int J Parasitol 34: 527533.
97. Pica-Mattoccia L,, Doenhoff MJ,, Valle C,, Basso A,, Troiani A-R,, Liberti P,, Festuci A,, Guidi A,, Cioli D. 2009. Genetic analysis of decreased praziquantel sensitivity in a laboratory strain of Schistosoma mansoni. Acta Trop 111: 8285.
98. Liang YS,, Coles GC,, Doenhoff MJ,, Southgate VR. 2001. In vitro responses of praziquantel-resistant and -susceptible Schistosoma mansoni to praziquantel. Int J Parasitol 31: 12271235.
99. Lamberton PHL,, Hogan SC,, Kabatereine NB,, Fenwick A,, Webster JP. 2010. In vitro praziquantel test capable of detecting reduced in vivo efficacy in Schistosoma mansoni human infections. Am J Trop Med Hyg 83: 13401347.
100. Norton AJ,, Gower CM,, Lamberton PHL,, Webster BL,, Lwambo NJS,, Blair L,, Fenwick A,, Webster JP. 2010. Genetic consequences of mass human chemotherapy for Schistosoma mansoni: population structure pre- and post-praziquantel treatment in Tanzania. Am J Trop Med Hyg 83: 951957.
101. Huyse T,, Van den Broeck F,, Jombart T,, Webster BL,, Diaw O,, Volckaert FAM,, Balloux F,, Rollinson D,, Polman K. 2013. Regular treatments of praziquantel do not impact the genetic make-up of Schistosoma mansoni in northern Senegal. Infect Genet Evol 18: 100105.


Generic image for table

Selected antiparasitic agents and susceptibility testing methods

Citation: Le Bras J, Clain J, Secor W. 2015. Susceptibility Test Methods: Parasites, p 2563-2571. In Jorgensen J, Pfaller M, Carroll K, Funke G, Landry M, Richter S, Warnock D (ed), Manual of Clinical Microbiology, Eleventh Edition. ASM Press, Washington, DC. doi: 10.1128/9781555817381.ch151

This is a required field
Please enter a valid email address
Please check the format of the address you have entered.
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error